Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression

被引：0
|
作者：
Rosenberg, J. [1 ]
Necchi, A. [2 ]
Sweis, R. F. [3 ]
Nakajima, K. [4 ]
Lu, C. [5 ]
Nogai, H. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Ist Nazl Tumori Milano Fdn IRCCS, Med Oncol, Milan, Italy
[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Bayer HealthCare Pharmaceut, Clin Dev, Whippany, NJ USA
[5] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA
[6] Bayer AG, Oncol, Berlin, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
925TiP
引用
收藏
页码：329 / 329
页数：1
相关论文
共 50 条
  • [31] Re: FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2024, 211 (01): : 199 - 200
  • [32] A prospective phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: PECULIAR study
    Choi, Y. J.
    Lee, J.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, B.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S658 - S658
  • [33] FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression
    Quinn, David I.
    Petrylak, Daniel Peter
    Bellmunt, Joaquim
    Necchi, Andrea
    Gurney, Howard
    Lee, Jae-Lyun
    Van Der Heijden, Michiel Simon
    Rosenbaum, Eli
    Penel, Nicolas
    Pang, See-Tong
    Li, Jian-Ri
    del Muro, Xavier Garcia
    Joly, Florence
    Papai, Zsuzsanna
    Ellinghaus, Peter
    Lu, Chengxing
    Nakajima, Keiko
    Ishida, Tatiane
    Nishiyama, Hiroyuki
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
    Rosenberg, J. E.
    Galsky, M. D.
    Balar, A. V.
    Loriot, Y.
    Necchi, A.
    Hoffman-Censits, J.
    Srinivas, S.
    Drakaki, A.
    Javery, A.
    Nelson, B.
    Huang, H. X.
    Shen, X.
    Van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S711 - S712
  • [35] Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
    Perez-Gracia, Jose Luis
    Hansen, Aaron Richard
    Eefsen, Rikke Helene Loevendahl
    Gomez-Roca, Carlos A.
    Negrier, Sylvie
    Pedrazzoli, Paolo
    Lee, Jae-Lyun
    Gordoa, Teresa Alonso
    Rodriguez, Cristina Suarez
    Mellado, Begona
    Moreno, Victor
    Rodriguez-Vida, Alejo
    Hussain, Arif
    Getzmann, Nicole
    Dejardin, David
    Boetsch, Christophe
    Kraxner, Anton
    Vardar, Taner
    Teichgraber, Volker
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Gemcitabine and oxaliplatin combination:: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
    Carles, Joan
    Esteban, E.
    Climent, M.
    Font, A.
    Gonzalez-Larriba, J. L.
    Berrocal, A.
    Fabregat, X.
    Albanell, J.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2006, 17 : 151 - 152
  • [37] Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
    Carles, J.
    Esteban, E.
    Climent, M.
    Font, A.
    Gonzalez-Larriba, J. L.
    Berrocal, A.
    Garcia-Ribas, I.
    Marfa, X.
    Fabregat, X.
    Albanell, J.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2007, 18 (08) : 1359 - 1362
  • [38] A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors
    Gabrail, Nashat Y.
    Tolcher, Anthony
    Alese, Olatunji B.
    Cecchini, Michael
    Manish, Patel
    Park, Haeseong
    Berlin, Jordan
    Hamilton, Erika P.
    Huang, Yingjie
    Lu, Lingmin
    Wang, Jianming
    Shi, Michael
    Tong, Ming F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Rosenberg, J. E.
    Milowsky, M.
    Ramamurthy, C.
    Mar, N.
    Mckay, R. R.
    Friedlander, T.
    Ferrario, C.
    Bracarda, S.
    George, S.
    Moon, H.
    Geynisman, D.
    Petrylak, D. P.
    Borchiellini, D.
    Burgess, E. F.
    Rey, J. P. Maroto
    Carret, A-S.
    Yu, Y.
    Guseva, M. V.
    Moreno, B. Homet
    O'Donnell, P. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1441 - S1441
  • [40] A phase II study of Irinotecan (Irino®) in combination with cisplatin as second line chemotherapy in patients with metastatic or locally advanced gastric cancer
    Shen, W-C
    Yang, T-S
    Chen, P-T
    Chen, J-S
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A21 - A21
12345